1. SF3B1 Overview
- Gene Name: SF3B1 (Splicing Factor 3B Subunit 1)
- Chromosome: 2q33.1
- Protein Function:
- Part of the U2 small nuclear ribonucleoprotein (snRNP) complex
- Essential for pre-mRNA splicing at branch points
- Ensures correct exon-intron recognition during splicing
2. Pathophysiology
- Mutations in SF3B1 → abnormal splicing → production of aberrant transcripts → dysregulated protein expression → tumorigenesis
- Most common mutation hotspots: codon K700, K666, R625
- Frequently causes use of cryptic 3′ splice sites
3. Tumors / Diseases Associated with SF3B1 Mutations
| Disease | Notes |
|---|---|
| Myelodysplastic syndromes (MDS) | ~20–30%, especially MDS with ring sideroblasts; associated with better prognosis |
| Chronic lymphocytic leukemia (CLL) | ~10–15%; associated with poor prognosis |
| Uveal melanoma | ~15–25%; associated with poor prognosis in certain subtypes |
| Breast, pancreatic, and other cancers | Rare; emerging research |
4. Clinical Implications
- Prognostic marker:
- In MDS with ring sideroblasts, SF3B1 mutation predicts better overall survival and a lower risk of progression to AML
- In CLL, associated with resistance to chemoimmunotherapy and poorer outcomes
- Therapeutic targeting:
- Currently no approved direct SF3B1 inhibitors, but splicing modulators are in clinical trials
- Luspatercept (for anemia in MDS with ring sideroblasts) indirectly addresses consequences of SF3B1 mutation
5. Mechanism Summary
- Normal: SF3B1 → guides spliceosome → proper mRNA → normal protein
- Mutated: SF3B1 → aberrant spliceosome → abnormal mRNA → dysregulated protein → clonal proliferation / tumorigenesis
Key Takeaways
- SF3B1 is a core spliceosome component, and mutations drive specific cancers via aberrant splicing.
- MDS with ring sideroblasts is the most clinically relevant context.
- Emerging therapies targeting splicing or downstream effects are in development.